To ensure the generalizability of clinical trial results and equitable treatment access, enrollment must reflect the diversity of the patient population.
Vol.26/No.10
Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.
Balazs Halmos, MD, MS, and Jamie E. Chaft, MD, discuss how safety considerations contribute to treatment selection in NSCLC.
Maurie Markman, MD, discusses the role of decision support tools in cancer management.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5